Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Evonne Hickok

Nurse Practitioner, Primary Care Williston, ND Nurse Practitioner

NPI 1013322387 CMS profile 10689068

1321 W Dakota Pkwy, Williston, ND 58801

Open in the dashboard

General payments

$144

5 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Evonne Hickok of Williston, ND is reported in the CMS Open Payments database as having received $144 across 5 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 34th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $55 3
2024 General $20 1
2022 General $69 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Evonne Hickok
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Evonne Hickok were reported at $55. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Evonne Hickok Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $137 $39–$445 $132
2022 $69 $139 $44–$421 $149
2023 $0 $163 $53–$481 $160
2024 $20 $176 $54–$511 $164
2025 $55 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novo Nordisk Inc $69 1 payment
  2. Medtronic, Inc. $53 3 payments
  3. Exact Sciences Corporation $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $144 5 payments
Products named General payments · program years 2022–2025
  1. RYBELSUS $69 1 payment
  2. MINIMED 780G $36 2 payments
  3. The Cologuard Plus Collection Kit $22 1 payment
  4. INPEN SMART INSULIN DELIVERY SYSTEM $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

1,268

Median for Nurse Practitioner: 389

Drug cost

$54,338

Median for Nurse Practitioner: $21,885

Branded share of claims

21.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rybelsus Semaglutide Brand 15 $13,988
Januvia Sitagliptin Phosphate Brand 14 $11,944
Farxiga Dapagliflozin Propanediol Brand 16 $8,613
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 11 $5,031
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 11 $1,665
Levothyroxine Sodium Generic 128 $1,007
Rosuvastatin Calcium Generic 77 $842
Albuterol Sulfate Hfa Albuterol Sulfate Brand 24 $750
Atorvastatin Calcium Generic 75 $614
Ventolin Hfa Albuterol Sulfate Brand 11 $595

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$33,851

Of which drugs: $16,305

Medicare patients

162

Average age 71

Services billed

1,249

112 women, 50 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 35%
Diabetes 24%
COPD 22%
Depression 16%
Heart failure 14%
Ischemic heart disease 14%
Cancer 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 15 15 $1,027

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

5 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record